Haleon plc filings document foreign private issuer disclosures for a global consumer health company whose American depositary shares trade under HLN. Form 6-K reports cover current information such as trading statements, ordinary-share repurchases for cancellation, total voting rights and capital, and annual general meeting poll results.
The filing record also includes debt-market disclosures, including listing particulars for the Euro Medium Term Note programme of Haleon UK Capital plc and Haleon Netherlands Capital B.V. guaranteed by Haleon. Governance and capital-structure disclosures address directors' remuneration, board elections, dividend approvals, special resolutions, ordinary shares, treasury shares, voting rights and shareholder notification thresholds.
Haleon plc announced the purchase and cancellation of 1,590,000 ordinary shares under the second tranche of its share buyback programme announced 31 July 2025. Following settlement, the company's registered share capital is 8,952,824,051 ordinary shares of £0.01 each, with 1,580,205 held as treasury shares, leaving 8,951,243,846 ordinary shares with voting rights. The announcement directs readers to a full trade breakdown under the Market Abuse Regulation and notes the notice does not constitute an offer for securities. Contact and investor website information are provided.
Haleon plc reports the purchase and cancellation of 1,200,000 ordinary shares under the second tranche of its share buyback programme announced 31 July 2025. After settlement the company's registered share capital is 8,954,414,051 ordinary shares of £0.01 each, with 1,580,205 held as treasury shares, leaving 8,952,833,846 ordinary shares with voting rights. The announcement notes a full breakdown of individual trades is available via the provided link and on the company website. The notice clarifies it is not an offer for securities and provides contact/signature details for the company secretary.
Haleon plc (LSE/NYSE:HLN) announced PDMR notifications describing grants of share awards under its Share Value Plan and Performance Share Plan. The Performance Share Plan (Interim) awards vest in March 2028 subject to continued employment and performance conditions covering the period ending 31 December 2027; the relevant performance targets were disclosed in Haleon’s 2024 Annual Report and Form 20-F. The Share Value Plan (Buyout) awards are subject to continued employment. All awards were made in line with Haleon’s Directors' Remuneration Policy and are subject to malus and clawback provisions.
The filing discloses aggregate award volumes including items of 192,571 and 405,911 (shares/ADS) and notes that some volumes are Nil where applicable. No financial amounts, prices, or additional compensation details are provided in this report.
Haleon plc announced on 05 September 2025 that it purchased and cancelled 353,360 ordinary shares of £0.01 each under the second tranche of its buyback programme announced 31 July 2025. After settlement the company's registered share capital is 8,955,614,051 ordinary shares, of which 3,880,205 are held as treasury shares, leaving 8,951,733,846 ordinary shares with voting rights. A full breakdown of individual trades is available at the provided RNS link and on the company website. The announcement states it does not constitute an offer or solicitation in any jurisdiction.
Haleon plc reports the purchase and cancellation of 354,000 ordinary shares of each under the second tranche of its share buyback programme announced 31 July 2025. Following settlement, registered share capital is 8,955,967,411 ordinary shares, of which 3,880,205 are held as treasury shares, leaving 8,952,087,206 ordinary shares with voting rights. The announcement notes the trade venue (London Stock Exchange CBOE (UK)/CXE) and provides a link to a full breakdown of individual trades. The company also states this is not an offer for securities and that details are available on its investor website.
Haleon plc announced the purchase and cancellation of 2,900,000 ordinary shares under the second tranche of its share buyback programme. After settlement, the company’s registered share capital is 8,956,321,411 ordinary shares of £0.01 each, with 3,880,205 held as treasury shares, leaving 8,952,441,206 ordinary shares with voting rights. The company provided a link to a full breakdown of individual trades and noted the announcement does not constitute an offer for securities. The buyback transaction was executed on the London Stock Exchange and details are posted on the company website.
Haleon plc reported its total issued share capital and voting rights. The company has 8,959,221,411 ordinary shares of each, of which 3,880,205 are held in treasury, leaving 8,955,341,206 ordinary shares with voting rights. Shareholders and others with notification obligations should use the voting-rights figure as the denominator for FCA notification calculations and may send notifiable interests to company.secretary@haleon.com. The filing also provides a brief company description noting Haleon (LSE/NYSE: HLN) is a global consumer health company with major brands across Oral Health, VMS, Pain Relief, Respiratory, Digestive and Therapeutic Skin Health.
Haleon plc announces it purchased 2,062,463 ordinary shares of
Haleon plc reports the purchase and cancellation of 2,191,437 ordinary shares of each as part of the second tranche of its buyback programme announced 31 July 2025.
Trades executed on 28 August 2025 totalled 2,191,437 shares at prices reported on the London Stock Exchange/CBOE (UK)/CXE with an average indicative price shown in the announcement. After settlement, registered share capital is 8,961,283,874 ordinary shares, with 3,880,205 held in treasury, leaving 8,957,403,669 ordinary shares carrying voting rights. The company provides a link to a full breakdown of individual trades and notes the announcement is not an offer for securities. More details are available on the company website.
Haleon plc announces it purchased 2,875,831 ordinary shares of £0.01 each for cancellation under the second tranche of its share buyback programme announced 31 July 2025. Following settlement, registered share capital is 8,963,475,311 ordinary shares, with 3,880,205 held as treasury shares, leaving 8,959,595,106 ordinary shares with voting rights. A full breakdown of the individual trades is provided via the linked RNS PDF and will also be available on the Company's investor website. The announcement clarifies it does not constitute an offer for securities.